PDCD4 and colorectal carcinoma: In the MZ-CRC-1 cell line treated with anti-miR-21, the expression of PDCD4 mRNA increased by 15.8% (p=0.0063) compared to the Negative Control#1; treatment with cabozantinib alone prompted the expression by 4.17-fold (p<0.001); and when the two treatments were combined, PDCD4 mRNA expression levels rose by 4,48-fold (p<0.001).